Featured StoriesInvestor NewsInvestor RelationsNewsPress ReleasesPublicity

Premier Biomedical Pain Management Solutions Announces Launch of Their PainReliefMeds.com Website

Posted at January 31, 2017 | By : | Categories : Featured Stories,Investor News,Investor Relations,News,Press Releases,Publicity | 0 Comment

Finally!

El Paso, Texas, January 31, 2017Premier Biomedical, Inc. (OTCQB: “BIEI“) announced the long awaited launch of their www.painreliefmeds.com website.  The website will initially sell pain relief patches and roll-ons, but will expand to include other pain relief products as they are launched later this calendar year.  The website complements their expanding distribution network through health-oriented direct distributors.   All of their products are drug-test-safe, opioid-free, and non-psychoactive.

The pain relief patches consist of a proprietary CBD hemp oil formulation with 20% more CBD, and a patch area 30% larger than competition, and are designed to provide up to 96 hours of continuous pain relief.  The roll-on contains 110 mg of our proprietary CBD formulation, 10% more CBD than the closest competitor, in an easy to use applicator.

William A. Hartman, President & CEO of PBPMS, stated, “We are very excited to have finally overcome the numerous stumbling blocks which have caused us to delay the launch of our e-commerce website, and to begin selling our products.  We can now turn our attention to ramping up production to meet the anticipated demand, and to focus on the development of additional pain relief products to complement these initial products.  We intend to launch creams, sprays, gel pens and capsules/tablets in the coming months.  We anticipate that these revenue-producing products will help us reduce or eliminate our dependence on dilutive borrowing, and should advance our stock price accordingly.”

Visit us at www.painreliefmeds.com

For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
w.hartman@premierbiomedical.com
http://www.premierbiomedical.com/

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans.  Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent.  Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP).  The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.”  For more information please visit our website: www.premierbiomedical.com.

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995).  Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.